MedTrace Logo

The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II

NCT03452085 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-03-02

No results posted yet for this study

Summary

In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with each product. Whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin.

The artificial saliva spray reduced the xerostomia and the inflammation or the oral tissue.

Conditions

  • Xerostomia Due to Hyposecretion of Salivary Gland
  • Diabetes Mellitus, Type 2

Interventions

DEVICE

artificial saliva spray (AS)

cross over design

OTHER

maritime throat spray (TT)

cross over design

Sponsors & Collaborators

  • Certmedica International GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-23
Primary Completion
2017-11-04
Completion
2018-01-16

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452085 on ClinicalTrials.gov